Role of targeted therapy in metastatic colorectal cancer

Table 3 Clinical trials comparing anti-epidermal growth factor receptor therapy vs anti-vascular endothelial growth factor therapy in metastatic colorectal cancer with KRAS wild type

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
First-line chemotherapy
PEAK	FOLFOX + Panitumumab	142	57.8%	10.9	34.2
	FOLFOX + Bevacizumab	143	53.5%	10.1	24.3
	(HR, P-value)		-	HR = 0.87	HR = 0.62
				P = 0.353	P = 0.009
FIRE-3	FOLFIRI + Cetuximab	297	62%	10.0	28.7
	FOLFIRI + Bevacizumab	295	58%	10.3	25.0
	(HR, P-value)		OR = 1.18	HR = 1.06	HR = 0.77
			P = 0.18	P = 0.55	P = 0.017
CALGB/SWOG 80405	Chemotherapy1 + Cetuximab	578	65.6%	10.4	29.9
	Chemotherapy1 + Bevacizumab	559	57.2%	10.8	29.0
	(HR, P-value)		P = 0.02	HR = 1.04	HR = 0.925
				P = 0.55	P = 0.34
Second-line chemotherapy
SPIRITT	FOLFIRI + Panitumumab	91	32%	7.7	18.0
	FOLFIRI + Bevacizumab	91	19%	9.2	21.4
	(HR, P-value)		-	HR = 1.01	HR = 1.06
				P = 0.97	P = 0.75

¹Chemotherapy regimens were FOLFOX or FOLFIRI. ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; HR: Hazard ratio; OR: Odds ratio; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin.